Verus International Inc (VRUS)

Pharmasset, Inc. was incorporated under the laws of Delaware on June 8, 2004. It is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. The Company's primary focus is on the development of nucleoside/tide analogs as oral therapeutics for the treatment of chronic hepatitis C virus (HCV) infection. Nucleoside/tide analogs are a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. It currently has three clinical-stage product candidates, two of which it is developing ourselves and one of which it is developing with a strategic partner. It is also advancing a series of preclinical candidates in preparation for clinical development. The Company's three clinical stage product candidates are: RG7128, an HCV cytosine nucleoside polymerase inhibitor it is developing through a strategic collaboration with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc; PSI-7977, an HCV uracil nucleotide analog polymerase inhibitor that is in a 12-week Phase 2b study in combination with SOC in patients with HCV genotypes 1, 2 or 3; and PSI-938, an HCV guanine nucleotide analog polymerase inhibitor that is screening patients for Part 2 of a Phase 1 study with PSI-7977 in patients with HCV genotype 1. Regulation by governmental authorities in the United States and other countries is a significant factor in the development, manufacture and marketing of pharmaceutical products and in research and development activities.